NAMD Provides Thoughts on High-Cost Drugs to Senate Finance
In March 2016, NAMD responded to a Senate Finance Committee Request for Information on prescription drug costs and coverage.
In March 2016, NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these drugs on the Medicaid program.
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
Drop us your email and we’ll keep you up-to-date on Medicaid issues.